Genetic manipulation of the ␣2A-adrenergic receptor (␣2A-AR) in mice has revealed the role of this subtype in numerous responses, including agonist-induced hypotension and sedation. Unexpectedly, ␣2-agonist treatment of mice heterozygous for the ␣2A-AR (␣2A-AR ؉/؊ ) lowers blood pressure without sedation, indicating that more than 50% of ␣2A-AR must be activated to evoke sedation. We postulated that partial activation of ␣2A-AR in wild-type ␣2A-AR ؉/؉ animals could be achieved with partial agonists, agents with variable ability to couple receptor occupancy to effector activation, and might elicit one versus another pharmacological response. In vitro assays reveal that moxonidine is a partial agonist at ␣2A-AR. Although moxonidine was developed to preferentially interact with imidazoline binding sites, it requires the ␣2A-AR to lower blood pressure because we observe no hypotensive response to moxonidine in ␣2A-AR-null (␣2A-AR ؊/؊ ) mice. Moreover, we observe that moxonidine lowers blood pressure without sedation in wild-type mice, consistent with the above hypothesis regarding partial agonists. Our findings suggest that weak partial agonists can evoke response-selective pathways and might be exploited successfully to achieve ␣2A-AR pharmacotherapy where concomitant sedation is undesirable, i.e., in treatment of depression or attention deficit hyperactivity disorder, in suppression of epileptogenesis, or enhancement of cognition. Furthermore, rigorous physiological and behavioral assessment of mice heterozygous for particular receptors provides a general strategy for elucidation of pathways that might be selectively activated by partial agonists, thus achieving response-specific therapy.
O ne approach to refining therapeutic specificity is to develop subtype-selective agents to activate or block receptor response. Gene manipulation in mice reveals which receptor subtype elicits a particular physiological or behavioral response in vivo, and has revealed the crucial role of the ␣ 2A -adrenergic receptor (␣ 2A -AR) subtype in mediating the ability of ␣ 2 -agonists to elicit hypotension (1-3), sedation (4), anesthetic sparing and analgesia (4, 5) , hypothermia (6, 7) , synergism with opiates in the antinociceptive response (5) , and enhancement of working memory in mice (10) . The latter finding suggests that the beneficial effects of guanfacine in working memory in primates (11) and in the enhancement of attentional focus in patients with attention deficit hyperactivity disorder (12) is attributable to ␣ 2A -AR actions. The ␣ 2A -AR subtype also is implicated in endogenous catecholamine-mediated suppression of epileptogenesis (8) and protection in models of depression and anxiety (9) . The sedative properties of ␣ 2 -agonists, valuable when used as preanesthetic or anesthetic sparing agents, limit their usefulness in cognitive enhancement (13, 14) or in treating attentional deficits (12, 15, 16) . Thus, subtype-selective agonists alone cannot assure optimized therapeutic intervention. However, the present findings suggest that differing ␣ 2A -AR responses can be selectively triggered by low-efficacy partial agonists at ␣ 2A -AR, and that rigorous characterization of mice heterozygous for a particular receptor may provide a general strategy for inferring which receptor-mediated effects might by amenable to this pharmacological approach. (2) mice, all on the C57BL/6 background, were maintained at the Vanderbilt University Animal Care Facility in accordance with procedures of the Animal Welfare Act and the 1989 Amendments to this Act.
Cell Culture. Cells stably expressing HA-tagged WT mouse ␣ 2A -AR at two different densities (HEK 293: 7.6 pmol/mg protein, and NIH 3T3: 0.82 pmol/mg protein) were maintained in DMEM supplemented with 10% FCS and 100 units/ml penicillin G sodium with 100 g/ml streptomycin sulfate.
Measurement of Cardiovascular Responses. Male mice (8-12 weeks of age, Ͼ30 g) were anesthetized with 50 mg/kg sodium pentathol. The left femoral artery and right jugular vein were catheterized with PE-10 polyvinyl tubing. After 48 hours, the arterial catheter was connected by a TXD-300 Pressure transducer to a Gould Amplifier (Orlando, FL); systolic, diastolic, and mean arterial blood pressure and heart rate were recorded continually on a Blood Pressure Analyzer (MicroMed, Portsmouth, NH) and Gould 8 Channel Recorder. Stability of the baseline was established by infusions of saline through the right jugular vein. Vehicle (saline) injections had no effect on the cardiovascular responses. The ␣ 2 -agonists were evaluated at 10 g/kg body weight for dexmedetomidine and 300 g/kg for moxonidine.
Measurement of Sedative Responses. Male mice (8-12 weeks of age, Ͼ30 g) were evaluated in the rotarod and loss of righting reflex tests of sedation, as described (4). Mice were injected i.p. with saline or a single bolus dose of the indicated ␣ 2 -agonist. Sedation was evaluated at 1,000 g/kg for moxonidine, brimonidine (UK 14,304), and clonidine, and 433 g/kg (maximal dose) or 2,165 g/kg (supramaximal dose) of dexmedetomidine.
Radioligand Binding. Assessing receptor density in mice of differing genotypes. Receptor density in mouse brains was evaluated as described (1) . Prazosin (1 M) was added to block radioligand binding to ␣ 2B -and ␣ 2C -AR subtypes in mouse brain (1 teins and thus any confounding effects of G protein regulation on receptor affinity for agonists. The K i for each ligand in competing for radioligand binding to the ␣ 2A -AR was calculated from the EC 50 for competition (17) . Receptor occupancy was calculated as 100% Ϫ % [ Stimulation of MAP kinase activity was assessed as described (18) . Parental cell backgrounds expressing no murine HA-␣ 2A -AR were also evaluated and demonstrated no MAP kinase activation in response to epinephrine (administered in the presence of 1 M propranolol to block endogenous ␤-adrenergic receptors, should they exist), clonidine, dexmedetomidine, or moxonidine. S] binding as described (19) .
Results
Sedation Requires Greater than 50% ␣2A-AR Activation. We initially manipulated the ␣ 2A -AR in mice by introducing a point mutation (D79N) into the ␣ 2A -AR locus by using hit-and-run homologous recombination strategies (1) . Characterization of these mice revealed that instability of the mutant receptor (20, 21) led to an Ϸ80% loss of steady state functional receptor density (1) in addition to the intended altered coupling of the ␣ 2A -AR to G proteins and downstream signaling pathways (22) . Mice expressing the D79N
) lost a variety of ␣ 2 agonist-mediated responses, including sedation ( Fig. 1; ref. 4) . Surprisingly, mice heterozygous for the D79N ␣ 2A -AR mutation
) also were not sedated in response to maximal (433 g/kg) or even supramaximal (2,165 g/kg) doses of the ␣ 2 -agonist dexmedetomidine. Sedation in heterozygous mice is also lost in response to the ␣ 2 -agonist UK 14,304, a clonidine analog (data not shown). Given the emerging literature on dimerization of G protein-coupled receptors (reviewed in refs. mice, but rather that greater than 50% of ␣ 2A -AR must be activated to evoke the sedative response.
Blood Pressure Lowering Requires Less than 50% ␣2A-AR Activation. In conscious, freely moving
WT mice, administration of dexmedetomidine evokes a transient hypertensive response followed by a longer-lived hypotensive response ( Fig. 2A) paralleled by a decrease in heart rate ( Fig. 2D ). The ␣ 2 -agonistelicited hypotensive response is lost in ␣ 2A -AR Ϫ/Ϫ knockout mice, whereas the transient pressor response, shown to involve the ␣ 2B -AR subtype (25) , is maintained and even exaggerated in these animals. Agonist treatment of mice heterozygous for the ␣ 2A -AR similarly elicits a prolonged hypotensive response ( mice (see Fig. 1 ). The finding that heterozygous animals retain cardiovascular responses but lose sedative effects to ␣ 2 -agonists provides definitive evidence that differing fractional activation of ␣ 2A -AR is critical for evoking different receptor-mediated responses and suggests that selective manipulation of ␣ 2A -AR-mediated responses in different clinical settings, using drugs rather than differing receptor density to differentially activate the total receptor population, could provide response-specific therapy. Partial agonists, which induce or stabilize a receptor conformation that is less efficient in coupling to downstream effector systems (26) , represent potential agents for eliciting a desired therapeutic endpoint (e.g., antihypertensive responses) without unwanted side effects (e.g., sedation). WT mice (Fig. 3 A and C) , albeit to 64% of the maximal hypotensive response elicited by dexmedetomidine. The role of the ␣ 2A -AR subtype in mediating these effects of moxonidine is conclusively demonstrated by the loss of moxonidine-elicited hypotension (Fig. 3B ) and bradycardia (Fig. 3D ) in conscious, freely moving ␣ 2A -AR Ϫ/Ϫ knockout mice, consistent with previous findings in D79N ␣ 2A -AR mice (29) . The ability of moxonidine to lower blood pressure in
mice is not paralleled by a sedative response in these animals (Fig. 4) .
Although moxonidine was developed as an agent preferential for I 1 -imidazoline binding sites with an intentionally reduced affinity at ␣ 2 -ARs (27), moxonidine possesses an affinity at the ␣ 2A -AR indistinguishable from that of epinephrine (Fig. 5A) . We evaluated the ability of moxonidine to activate MAP kinase in cells expressing ␣ 2A -AR at 0.82 pmol/mg protein (Fig. 5C) , a density comparable to that in mouse brain homogenates (0.2 pmol ␣ 2A -AR/mg protein; ref. 1). Dexmedetomidine, clonidine, and moxonidine all behave as partial agonists relative to epinephrine in activating MAP kinase, eliciting 74%, 64%, and 34% of the maximal response of epinephrine, respectively. Because the ability of partial agonists to activate biological systems can be increased in settings of increased receptor density (28), we evaluated the ability of agonists to activate MAP kinase in cells expressing ␣ 2A -AR at a nearly 10-fold greater receptor density, i.e., 7.6 pmol/mg protein. As demonstrated in Fig. 5D , the % maximal response for dexmedetomidine, clonidine, and moxonidine increased to 121%, 103%, and 83% of epinephrine, respectively, at this greater receptor density.
In cells overexpressing the ␣ 2A -AR at 7.6 pmol/mg protein, we also evaluated agonist stimulation of GTP[␥ 35 S] binding (Fig.  5B) . Moxonidine behaves as a less efficacious agonist than epinephrine in this in vitro system as well, achieving 77% of epinephrine, consistent with previous in vitro findings at human ␣ 2A -AR (29) . Interestingly, a comparison of MAP kinase activation versus stimulation of GTP[␥ 35 S] binding reveals that at 7.6 pmol/mg protein, dexmedetomidine is a ''superagonist'' (121% activation) of MAP kinase but a partial agonist (88% stimulation) of GTP[␥ 35 S] binding.
Discussion
The present findings provide several novel insights. First, heterozygous ␣ 2A -AR ϩ/Ϫ animals retain cardiovascular responses to ␣ 2 -agonists but, interestingly, are not sedated even at supramaximal doses of dexmedetomidine (Fig. 1) or UK 14,304 (data not shown). These data provide definitive genetic evidence that sedation requires activation of greater than 50% of the ␣ 2A -AR population, consistent with the interpretation of previous studies in rats using covalent inactivation of amine-binding receptors (30) or regional antisense strategies (31) to incrementally diminish ␣ 2A -AR density. Our data affirm the formal possibility that differing fractional activation of receptors might evoke different receptor-mediated responses in different tissues, or in different neural pathways. In the presence of a full receptor complement (i.e., ␣ 2A -AR ϩ/ϩ WT animals), differing fractional activation can be achieved either by administering incremental doses of a full agonist or by exploiting drugs that have diminished effectiveness in coupling receptor occupancy to effector activation, known as partial agonists.
Our data reveal that moxonidine, an agent developed to selectively interact with I 1 -imidazoline binding sites, requires the ␣ 2A -AR to elicit its effects: no hypotensive response to moxonidine occurs in ␣ 2A -AR Ϫ/Ϫ mice (Fig. 3B) , though we cannot rule out the possibility that moxonidine also has independent effects, perhaps via I 1 -imidazoline binding sites, upstream of the heterozygous animals in response to full or strong agonists, i.e., selectively lowering blood pressure without evoking sedation, thus mimicking the clinical profile of moxonidine in human beings (33, 34) . The sedation-free hypotensive effects of moxonidine may result both from its lower efficacy and its moderate affinity at ␣ 2A -AR. Thus, moxonidine is 34% as effective as epinephrine in activating MAP kinase in cells expressing 0.82 pmol ␣ 2A -AR/mg ( Fig. 5 C and E) and is nonsedating. In contrast, clonidine and dexmedetomidine are 64% and 74%, respectively, as effective as epinephrine in activating MAP kinase (i.e., are above the 50% ''threshold'' suggested in studies of ␣ 2A -AR ϩ/Ϫ heterozygous mice) and are sedating in vivo. However, it should also be noted that clonidine and dexmedetomidine have a much higher affinity at ␣ 2A -AR than either epinephrine or moxonidine (Fig. 5A) ; in vivo, their partial agonism may be compensated for, at least in part, by their longer lived receptor occupancy. However, we must acknowledge that in vitro assays are, at best, capricious predictors of in vivo response. First, we do not know the precise receptor density of the target cells or cellular pathway(s) in vivo. Furthermore, efficacy can vary for coupling to different effectors. For example, at 7.6 pmol ␣ 2A -AR/mg protein, dexmedetomidine is a partial agonist (88%) in evoking GTP[␥ 35 S] binding but a ''superagonist'' (121% of the maximal response to epinephrine) in eliciting MAP kinase activation (see Fig. 5 B and D) .
Our studies unveil a generalizable strategy, i.e., assessing physiological and behavioral responses in mice heterozygous for a particular receptor, to explore whether or not partial agonists might provide highly selective, if not response-specific, therapeutic tools in a particular setting. In cases where one but not another receptor-mediated response is lost in heterozygous animals, subsequent studies could identify partial agonists that are sufficiently efficacious to evoke a desired pharmacological response in WT mice but fortuitously ineffective in eliciting receptor-mediated responses associated with undesired clinical side effects.
Although mice heterozygous for particular G protein-coupled receptors have not been evaluated extensively, findings from mice heterozygous for the M2 muscarinic receptor reveal that greater than 50% receptor density is needed for oxotremorineelicited tremors (35) , suggesting that partial agonists at M2 muscarinic receptors might achieve negative chronotropy without undesired tremorogenic side effects. This same conceptual framework has also proven useful for other receptor families. Thus, findings that mice heterozygous for the nuclear hormone receptor peroxisome proliferator-activated receptor ␥ had enhanced insulin sensitivity with reduced adipocyte differentiation (36, 37) led to the identification a peroxisome proliferatoractivated receptor ␥ partial agonist that significantly improves insulin sensitivity without significant adipogenic activity (38) . These examples suggest that detailed characterization of heterozygous animals may be a fruitful approach for the identification and development of response-specific therapeutic agents for a variety of disease states.
Our data demonstrate that moxonidine behaves as a partial, or less efficacious (39) , agonist at ␣ 2A -AR, and serves as a prototype for agents capable of selectively modulating cardiovascular responses without sedative side effects. Focusing on the development of ␣ 2A -AR partial agonists of differing relative efficacy could lead to refined strategies for treatment of attentional focus in attention deficit hyperactivity disorder (12, 16) or enhancement of cognition in the elderly (12) . In addition, because the ␣ 2A -AR subtype appears to suppress epileptogenesis (8) , it is provocative to speculate that partial ␣ 2A -agonists may provide the first antiepileptogenic agents, to complement the existing armamentarium of anticonvulsant drugs (40) . The protective role of the ␣ 2A -AR against measures of depression and anxiety in mouse models suggest that partial agonists at ␣ 2A -AR also might ameliorate these behavioral disorders in human beings. Achieving these therapeutic outcomes without concomitant sedation is an extremely attractive possibility, and the present data provide a definitive proof of concept that the development of partial ␣ 2A -agonists with limited efficacy could refine therapeutic specificity, thereby increasing the breadth of treatable physiological and behavioral diseases. Moxonidine does not cause sedation in ␣2A-AR ϩ/ϩ mice. Sedative responses to the ␣2-agonists UK 14,304, clonidine, moxonidine, or saline were measured as rotarod latency, or the time the mice were able to remain on a rotating bar. (The effects of dexmedetomidine were given in Fig. 1 .) UK 14,304 and clonidine (1,000 g/kg) are sedative in ␣2A-AR ϩ/ϩ mice, causing these mice to fall from the rotarod bar after 6 and 17 seconds, respectively. In contrast, moxonidine (1,000 g/kg) is indistinguishable from saline, e.g., nonsedating. * , No sedative response. Time 0 on the rotarod equals, by definition, 100% sedation. Data are the mean Ϯ SEM of 5 ␣2A-AR ϩ/ϩ mice for each ␣2-agonist evaluated. 
